Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 2004Expert Review of Cardiovascular Therapy

Losartan in diabetic nephropathy

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does losartan slow the progression of renal disease and reduce cardiovascular morbidity in patients with diabetic nephropathy?

Population

Patients with diabetic nephropathy (Type 1 and Type 2 diabetes mellitus)

Comparison

Losartan (angiotensin-type 1 receptor blocker) vs Conventional antihypertensive therapy or…

Design

Review

Authors

NPNorberto PericoPRPiero RuggenentiGRGiuseppe Remuzzi

Discussion

Loading...

Member takes

Overview

Supports losartan for renoprotection in diabetic nephropathy; leaves open optimal multidrug regimens for cardiovascular outcomes.

Structured PICO

Does losartan slow the progression of renal disease and reduce cardiovascular morbidity in patients with diabetic nephropathy?

P
Population
Patients with diabetic nephropathy (Type 1 and Type 2 diabetes mellitus)
I
Intervention
Losartan (angiotensin-type 1 receptor blocker)
C
Comparator
Conventional antihypertensive therapy or angiotensin-converting enzyme inhibitors
O
Outcome
Progression of overt diabetic nephropathy and albumin excretion rate

Losartan is an effective treatment for slowing the progression of diabetic nephropathy and reducing cardiovascular morbidity, supporting its use as part of a multidrug approach for renoprotection.

Cite This Study

Perico et al. (2004) studied this question.

synapsesocial.com/papers/6a8a99a9b1e5d05ea8ecafa5https://doi.org/10.1586/14779072.2.4.473
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Advances in the treatment of diabetic renal disease: focus on losartan2004 · 8 citations
  2. 2Optimal dose of losartan for renoprotection in diabetic nephropathy2002 · 70 citations
  3. 3Continuum of Renoprotection with Losartan at All Stages of Type 2 Diabetic Nephropathy2004 · 125 citations
  4. 4Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade2005 · 7 citations
  5. 5Losartan and end-organ protection-lessons from the renaal study2005 · 23 citations